Agreed. I believe MS still has its PT at $65. My guess is that JPM is projecting lower conversion rates for the wave 3 products and perhaps fewer co-formulation patents. Analysts will continue to have widely different estimates until there is more visibility. The pending challenge to Darzalex FasPro’s patent in Europe is a significant catalyst that I was surprised no one brought up.
News 
Market Data 
Discover 
